Business
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the f
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"Biocartis NV","displaySize":"","headline":null,"caption":"Biocartis NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/0fe4408e84484e3dec46a8e0dff7b143"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XXgeuPSAdzafod0gpnHjug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fe4408e84484e3dec46a8e0dff7b143","width":300,"height":300}},"lazy":false},{"type":"text","content":"PRESS RELEASE - 09/15/2025, 09:00 AM EDT","length":40,"tagName":"p"},{"type":"text","content":"Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test","length":60,"tagName":"p"},{"type":"text","content":"First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients","length":137,"tagName":"p"},{"type":"text","content":"Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the first-ever Premarket Approval (PMA) from the FDA for a cartridge-based, fully automated, “sample-to-result” companion diagnostic test.","length":398,"tagName":"p"},{"type":"text","content":"The Idylla™ CDx MSI Test aids in identifying eligible microsatellite instability-high (MSI-H) colorectal cancer (CRC) patients, who may benefit from treatment with OPDIVO® (nivolumab) alone, or in combination with YERVOY® (ipilimumab), as established in the CheckMate-8HW trial (Bristol Myers Squibb Company) (André et al., 20241; André et al., 20252)3.","length":353,"tagName":"p"},{"type":"text","content":"“The approval of this new MSI companion diagnostic for patients with colorectal cancer is a meaningful achievement from our collaboration with Biocartis and a strong reflection of our Precision Medicine strategy at Bristol Myers Squibb,” said Sarah Hersey, Vice President, Precision Medicine, Bioanalytical and Translational Sciences, Bristol Myers Squibb. “Rapid and accurate diagnosis is crucial to enabling access to appropriate therapeutic approaches, and this latest advancement exemplifies our commitment to delivering innovative, targeted solutions that have the potential to impro...